Home › Bell Radar › BLSM

BLSMBlossomHill Therapeutics

US ExchangeHealth Care2026-08-07

Clinical-stage biopharma developing small molecule medicines for oncology, including EGFR-mutant NSCLC and R/R AML.

$16IPO price

$150MRaised

$16Day-1 close

-1.25%Day-1 return

Clinical-stage biopharma developing small molecule medicines for oncology, including EGFR-mutant NSCLC and R/R AML.

Company description (source: StockAnalysis)

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incor...

医疗健康

51CFO read: CFO must handle oncology pipeline valuation, partnership deal structuring, and global clinical trial finance.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.

Talk to us